OTCMKTS:RNUGF - ReNeuron Stock Price, Price Target & More

$1.22 -0.13 (-9.63 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$1.35
Today's Range$1.22 - $1.22
52-Week Range$0.0160 - $1.35
Volume1,000 shs
Average Volume4,000 shs
Market Capitalization$38.61 million
P/E Ratio-1.22
Dividend YieldN/A
BetaN/A

About ReNeuron (OTCMKTS:RNUGF)

ReNeuron logoReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RNUGF News and Ratings via Email

Sign-up to receive the latest news and ratings for RNUGF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RNUGF
CUSIPN/A
Phone44-20-3819-8400

Debt

Debt-to-Equity RatioN/A
Current Ratio7.84%
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-1.22
Forward P/E Ratio-1.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$60,000.00
Price / Sales643.55
Cash FlowN/A
Price / CashN/A
Book Value$2.20 per share
Price / Book0.55

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares31,650,000

How to Become a New Pot Stock Millionaire

ReNeuron (OTCMKTS:RNUGF) Frequently Asked Questions

What is ReNeuron's stock symbol?

ReNeuron trades on the OTCMKTS under the ticker symbol "RNUGF."

When is ReNeuron's next earnings date?

ReNeuron is scheduled to release their next quarterly earnings announcement on Thursday, July, 5th 2018. View Earnings Estimates for ReNeuron.

Who are some of ReNeuron's key competitors?

Who are ReNeuron's key executives?

ReNeuron's management team includes the folowing people:
  • Mr. Olav Hellebø, Chief Exec. Officer and Director (Age 53)
  • Mr. Michael E. Hunt BSc, ACA, CFO, Sec. & Exec. Director (Age 55)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 67)
  • Dr. Randolph Corteling Ph.D., Head of Research
  • Ms. Sharon Grimster FSB, AFIChemE, BSc, DMS, VP of Devel. & GM of Wales (Age 59)

Has ReNeuron been receiving favorable news coverage?

Press coverage about RNUGF stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ReNeuron earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 44.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of ReNeuron?

Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ReNeuron's stock price today?

One share of RNUGF stock can currently be purchased for approximately $1.22.

How big of a company is ReNeuron?

ReNeuron has a market capitalization of $38.61 million and generates $60,000.00 in revenue each year. The company earns $-20,350,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact ReNeuron?

ReNeuron's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-20-3819-8400.


MarketBeat Community Rating for ReNeuron (RNUGF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  73
MarketBeat's community ratings are surveys of what our community members think about ReNeuron and other stocks. Vote "Outperform" if you believe RNUGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNUGF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ReNeuron (OTCMKTS:RNUGF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/21/2016 forward)

Earnings

Dividends

ReNeuron (OTCMKTS:RNUGF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ReNeuron (OTCMKTS RNUGF) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.08%
Insider Trading History for ReNeuron (OTCMKTS:RNUGF)

ReNeuron (OTCMKTS RNUGF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

ReNeuron (OTCMKTS RNUGF) News Headlines

Source:
DateHeadline
ReNeuron (RNUGF) Lowered to "Hold" at Zacks Investment ResearchReNeuron (RNUGF) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 11:07 AM
ReNeuron (RNUGF) Raised to Buy at Zacks Investment ResearchReNeuron (RNUGF) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:28 AM
ReNeuron (RNUGF) Stock Rating Lowered by Zacks Investment ResearchReNeuron (RNUGF) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 23 at 6:49 PM
Zacks Investment Research Upgrades ReNeuron (RNUGF) to "Buy"Zacks Investment Research Upgrades ReNeuron (RNUGF) to "Buy"
www.americanbankingnews.com - March 22 at 11:34 AM
Reneuron Group (RNUGF) Rating Increased to Buy at Zacks Investment ResearchReneuron Group (RNUGF) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 16 at 6:24 AM
Reneuron Gp (RNUGF) Raised to Buy at Zacks Investment ResearchReneuron Gp (RNUGF) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - January 25 at 11:16 PM
Reneuron Gp (RNUGF) Lifted to Buy at Zacks Investment ResearchReneuron Gp (RNUGF) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - January 14 at 8:14 AM
Reneuron Gp (RNUGF) Stock Rating Lowered by Zacks Investment ResearchReneuron Gp (RNUGF) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 6 at 7:02 AM
ReNeuron Group Proposes To Reorganise Current Share Capital (ALLISS)ReNeuron Group Proposes To Reorganise Current Share Capital (ALLISS)
www.morningstar.co.uk - January 5 at 8:38 AM
ReNeuron Half Year Loss Widens On Research Costs Amid Clinical ProgressReNeuron Half Year Loss Widens On Research Costs Amid Clinical Progress
www.morningstar.co.uk - December 14 at 8:58 AM

SEC Filings

ReNeuron (OTCMKTS:RNUGF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ReNeuron (OTCMKTS RNUGF) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.